• 2001.09—2006.09  皖南医学院临床医学专业本科生

• 2006.09—2011.07  中山大学中山医学院药理学专业博士研究生

• 2011.10—2017.10  美国芝加哥大学博士后研究员

• 2017.11—至今     williamhill官网青年研究员

• 2019，上海市“东方学者”特聘教授，上海市教委

• RNA稳态在恶性肿瘤发生发展和天然免疫中的作用研究

• 基于病毒载体的肿瘤基因治疗药物研发

• 2018，国家自然科学基金面上项目，“ATF3对恶性胶质瘤放疗敏感性的作用及机制”，主持

• 2019，上海市卫健委临床专项面上项目（项目编号：201940233），主持

• 2020，国家自然科学基金面上项目，“DNMT1在cAMP激动剂诱导胶质瘤定向分化中的作用及机制”，主持

本科生课程：

• 药理学、Medical Pharmacology、基础医学导论

研究生课程：

• 高级临床药理学、高级神经药理学、高级药理学进展

• 2015-今 担任Cancer Research ,Clinical Cancer Research, Oncogene等20种

• SCI学术期刊审稿专家

• 2017-今 Frontiers in Pharmacology   Editorial board member

• 2019-今 《中国临床药理学与治疗学》   编委

• Minfeng Shu, Te Du, Guoying Zhou and Bernard Roizman. The role of Activating Transcription Factor 3 in the synthesis of LAT and maintenance of HSV-1 in latent state in ganglia. Proc Natl Acad Sci U S A. 112(39): E5420-6 (2015).

• Minfeng Shu, Brunella Taddeo and Bernard Roizman. Tristetraprolin recruits the herpes simplex virion host shutoff RNase to the A-U rich elements in stress response mRNAs to enable their cleavage. Journal of Virology 89(10):5643-50 (2015)

• Minfeng Shu, Brunella Taddeo, Weiran Zhang and Bernard Roizman. Selective degradation of mRNAs by the HSV host shutoff RNase is regulated by the UL47 tegument protein. Proc Natl Acad Sci U S A. 110(18): E1669-75 (2013)

• Minfeng Shu, Brunella Taddeo and Bernard Roizman. The nuclear-cytoplasmic shuttling of virion host shutoff RNase is enabled by pUL47 and an embedded nuclear export signal and defines the sites of degradation of AU-rich and stable cellular mRNAs. Journal of Virology, 87(24): 13569-78 (2013)

• Minfeng Shu, Yuehan Zhou, Wenbo Zhu, Haipeng Zhang, Sihan Wu, Jingkao Chen,and Guangmei Yan. MicroRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/protein kinase A pathway. Molecular Pharmacology 81(3): 292-8 (2012)

• Minfeng Shu, Xiaoke Zheng , Sihan Wu, Huimin Lu, Tiandong Leng, Wenbo Zhu, Yuehan Zhou, Yanqiu Ou, Xi Lin, Yuan Lin, Dong Xu, Yuxi Zhou and Guangmei Yan. Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Molecular Cancer 19;10:59 (2011)

• Qian Liu , Ruotong Tian , Panpan Yu and Minfeng Shu*. miR-221/222 suppression induced by activation of the cAMP/PKA/CREB1 pathway is required for cAMP-induced bidirectional differentiation of glioma cells. FEBS Letters. 2021 Nov;595(22):2829-2843.

• Ruotong Tian, Yimin Li, Qian Liu and Minfeng Shu*. Identification and Validation of an Immune-Associated RNA-Binding Proteins Signature to Predict Clinical Outcomes and Therapeutic Responses in Glioma Patients. Cancers (Basel). 2021 Apr 6;13(7):1730.

• Ruotong Tian, Yimin Li and Minfeng Shu*. Circadian Regulation Patterns With Distinct Immune Landscapes in Gliomas Aid in the Development of a Risk Model to Predict Prognosis and Therapeutic Response. Frontiers in Immunology. 2022 Jan 6;12:797450.

• Rucheng Yan, Weiwei Dai, Ruixin Wu, Houbao Huang and Minfeng Shu*. Therapeutic targeting m6A-guided miR-146a-5p signaling contributes to the melittin-induced selective suppression of bladder cancer. Cancer Letters. 2022 May 28;534:215615.

国际PCT专利:

• Inventors: Minfeng Shu, Stephen Mallon, Ralph R.  Weichselbaum and Bernard Roizman.

  Title: METHODS AND COMPOSITIONS FOR TREATMENT OF IONIZING RADIATION RESISTANT TUMORS.

  Submission Number: 118603;

  Application Number:  PCT/CN2017/ 084712;

  Date of Receipt: 17 May 2017.

  Receiving Office: China Intellectual Property Office